Xenon Pharmaceuticals Inc. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d003a910-8bd3-4e05-8307-05cf418435b3/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $7.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076650 |
| FY 2024 | $0 | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-076650 |
| FY 2023 | $0 | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-076650 |
| FY 2022 | $9.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005582 |
| FY 2021 | $18.4M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-008060 |
| FY 2020 | $32.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009905 |
| FY 2019 | $6.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009385 |
| FY 2017 | $311.0k | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-006514 |
| FY 2016 | $1.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003716 |
| FY 2015 | $15.6M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014222 |
| FY 2014 | $28.4M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001612 |
| FY 2013 | $27.4M | 2013-01-01 – 2013-12-31 | evidence 0001564590-15-001612 |
| FY 2012 | $14.3M | 2012-01-01 – 2012-12-31 | evidence 0001564590-15-001612 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Xenon Pharmaceuticals Inc. — all facts · Net Income · Operating Income